Intrahippocampal administration of Aβ1-40 impairs spatial learning and memory in hyperglycemic mice

Neurobiology of Learning and Memory

Volumn 87, Issue 4, 2007, Pages 483-494

  Huang, Hei Jen ^a,b   Liang, Ken Chen ^c   Chen, Chie Pein ^d   Chen, Chiung Mei ^e   Hsieh Li, Hsiu Mei ^a  

^a NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Amyloid; Alzheimer's disease; Diabetes mellitus; Hippocampus; Spatial reference memory; Streptozotocin

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; DRUG VEHICLE; MONOMER; OLIGOMER; STREPTOZOCIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DENTATE GYRUS; HIPPOCAMPUS; HYPERGLYCEMIA; LEARNING DISORDER; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; STREPTOZOCIN DIABETES; TASK PERFORMANCE;

AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DISCRIMINATION LEARNING; HIPPOCAMPUS; HYPERGLYCEMIA; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICROINJECTIONS; NEURONS; PEPTIDE FRAGMENTS; SPATIAL BEHAVIOR;

EID: 33947574472     PISSN: 10747427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nlm.2006.11.006     Document Type: Article

References (62)

1. Auer R.N., and Siesjo B.K. Hypoglycemia: brain neurochemistry and neuropathology. Bailliere's Clinical Endocrinology and Metabolism 7 (1993) 611-625
2. Awad N., Gagnon M., and Messier C. The relationship between impaired glucose tolerances, type 2 diabetes, and cognitive function. Journal of Clinical and Experimental Neuropsychology 26 (2004) 1044-1080
3. Ball M.J., Fisman M., Hachinski V., Blume W., Fox A., Kral V.A., et al. A new definition of Alzheimer's disease: a hippocampal dementia. Lancet 279 (1985) 31374-31382
4. Biessels G.J., and Kappelle L.J. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology?. Biochemical Society Transactions 33 (2005) 1041-1044
5. Broe G.A., Henderson A.S., Creasey H., McCusker E., Korten A.E., Jorm A.F., et al. A case-control study of Alzheimer's disease in Australia. Neurology 40 (1990) 1698-1707
6. Buchsbaum M., Kesslak J., Lynch G.S., Chui H., Wu J., Sicotte N., et al. Temporal and hippocampal metabolic rate during an olfactory memory task assessed by positron emission tomography in patients with dementia of the Alzheimer type and controls. Archives of General Psychiatry 48 (1991) 840-847
7. Butterfield D.A., Drake J., Pocernich C., and Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends in Molecular Medicine 7 (2001) 548-554
8. Butterfield D.A., Hensley K., Harris M., Mattson M., and Carney J. Beta-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochemical and Biophysical Research Communications 200 (1994) 710-715
9. Chandrashekhar S.P., Vijay P.S., and Shrinivas K.K. Modulatory effect of sildenafil in diabetes and electroconvulsive shock-induced cognitive dysfunction in rats. Pharmacological Reports 58 (2006) 373-380
10. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nature Neuroscience 2 (1999) 271-276
11. Chen G., Chen K.S., Knox J., Inglis J., Bernard A., Justice A., et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408 (2000) 975-979
12. Dahlgren K.N., Manelli A.M., Stine W.B., Baker Jr. L.K., Krafft G.A., and Ladu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. Journal of Biological Chemistry 277 (2002) 32046-32053
13. Dominique S.R., Claire D., Berengere F., Audrey K., Georges L., Pierre A., et al. Early endothelial dysfunction severely impairs skin blood flow response to local pressure application in streptozotocin-induced hyperglycemic mice. Diabetes 53 (2004) 1564-1569
14. Duara R., Grady C., Haxby J., Sundaram M., Cutler N.R., Heston L., et al. Positron emission tomography in Alzheimer's disease. Neurology 36 (1986) 879-887
15. Duyckaerts C., Uchihara T., Seilhean D., He Y., and Hauw J.J. Dissociation of Alzheimer type pathology in a disconnected piece of cortex. Acta Neuropathologica 93 (1997) 501-507
16. Eckert A., Keil U., Marques C.A., Bonert A., Frey C., Schqssel K., et al. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochemical Pharmacology 66 (2003) 1627-1634
17. Edward H.L. Multiple low-dose streptozotocin-induced hyperglycemia and insulitis in C57BL mice: Influence of inbred background, sex, and thymus. Proceedings of the National Academy of Sciences of the United States of America 79 (1982) 630-634
18. Gispen W.H., and Biesswls G.J. Cognition and synaptic plasticity in diabetes mellitus. Trends in Neurosciences 23 (2000) 542-549
19. Gordon M.N., King D.L., Diamond D.M., Jantzen P.T., Boyett K.V., Hope C.E., et al. Correlation between cognitive deficits and Aβ deposits in transgenic APP+PS1 mice. Neurobiology of Aging 22 (2001) 377-385
20. Henderson A.S. The risk factors for Alzheimer's disease: a review and a hypothesis. Acta Psychiatrica Scandinavica 78 (1988) 257-275
21. Hsiao K.K., Borchelt D.R., Olson K., Johannsdottir R., Kitt C., Yunis W., et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15 (1955) 1203-1218
22. Hyman B.T., Van Hoesen G.W., Damasio A.R., and Barnes C.L. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 225 (1984) 1168-1170
23. Hyman B.T., Van Hoesen G.W., Kromer L.J., and Damasio A.R. Perforant pathway changes and the memory impairment of Alzheimer's disease. Annals of Neurology 20 (1986) 472-481
24. Ishibashi K., Tomiyama T., Nishitsuji K., Hara M., and Mori H. Absence of synaptophysin near cortical neurons containing oligomer Abeta in Alzheimer's disease brian. Journal of Neuroscience Research 84 (2006) 632-636
25. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., et al. A beta peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
26. Janus C., and Westaway D. Transgenic mouse models of Alzheimer's disease. Physiology and Behavior 73 (2001) 873-886
27. Jarrard L.E. The hippocampus and motivation. Psychological Bulletin 79 (1973) 1-12
28. John W.C., Geoffrey P.M., Kurt J.M., Allen P.Y., Donald P.C., and Rhoderick H.E. Increased susceptibility to streptozotocin-induced β-cell apoptosis and delayed autoimmune diabetes in alkylpurine-DNA-N-glycosylase-deficient mice. Molecular and Cellular Biology 21 (2001) 5605-5613
29. Kamal A., Biessels G.J., Duis S.E.J., and Gispen W.H. Learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: interaction of diabetes and ageing. Diabetologia 43 (2000) 500-506
30. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., and Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid beta protein in the Tg2567 transgenic mouse model of Alzheimer's disease. Journal of Neuroscience 21 (2001) 372-381
31. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
32. Kim H.I., Chae S.C., Lee D.K., Chromy B., Lee S.C., Park Y.C., et al. Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB Journal 17 (2003) 118-120
33. Kishi Y., Nickander K.K., Schmelzer J.D., and Low P.A. Gene expression of antioxidant enzymes in experimental diabetic neuropathy. Journal of the Peripheral Nervous System 5 (2000) 11-18
34. Lashuel H.A., Hartley D., Petre B.M., Walz T., and Lansbury P.T. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418 (2002) 291
35. Lothman E.W., Bertram E.H., and Stringer J.L. Functional anatomy of hippocampal seizures. Progress in Neurobiology 37 (1991) 1-82
36. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. American Journal of Pathology 155 (1999) 853-862
37. Matthew D., Smyth J., Patrick K., Brian J.C., and Carl W.C. Analysis of brain injury following intrahippocampal administration of β-amyloid in streptozotocin-treated rats. Neurobiology of Aging 15 (1994) 153-159
38. Mattson M.P., Cheng B., Davis D., Bryant K., Lieberburg I., and Rydel R.E. Beta-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. Journal of Neuroscience 12 (1992) 376-389
39. Mehrdad R., Mohammad T.J., Mohammad R.J., and Tourandokht B. Time course of changes in passive avoidance and Y-maze performance in male diabetic rats. Iranian Biomedical Journal 10 (2006) 99-104
40. Minako H., Michio S., Shinichiro M., Akihiko N., Kaori Y., Natsuko Y., et al. Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β. Proceedings of the National Academy of Sciences of the United States of America 100 (2003) 6370-6375
41. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
42. Morris R.G.M., Garrud P., Rawlins J.N., and O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 297 (1982) 681-683
43. Munch G., Schinzel R., Loske C., Wong A., Durany N., Li J.J., et al. Alzheimer's disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. Journal of Neural Transmission 105 (1998) 439-461
44. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 6 (1997) 403-409
45. Shengming Y., Zhuo G., Yiyuan T., Jie Z., Jaushyong H., and Wanqin Z. Abnormal expression of epilepsy-related gene ERG1/NSF in the spontaneous recurrent seizure rats with spatial learning memory deficits induced by kainic acid. Brain Research 1053 (2005) 195-202
46. Soroku Y., Shin-Ichiro Y., Ryu-ichi W., Masayuki B., Thomas C.H., Chihiro Y.N., et al. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 124 (2001) 2448-2458
47. Squire L.R. Mechanisms of memory. Science 232 (1986) 1612-1619
48. Stadelmann C., Deckwerth T.L., Srinivassan A., Bancher C., Bruck W., Jellinger K., et al. Activation of caspase-3 in single neurons and autophagic granules of granulovaculoar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. American Journal of Pathology 155 (1999) 1459-1466
49. Stefani M., and Dobson C.M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. Journal of Molecular Medicine 81 (2003) 678-699
50. Stubley L., Mungall B.A., and Wright J.W. The disruption of spatial and associative memories after kainic acid-induced selective hippocampal lesions in rats. Abstract Society for Neuroscience 20 (1994) 807
51. Su J., Zhao M., Anderson A.J., Srinivassan A., and Cotman C.W. Activated caspase-3 expression in Alzheimer's and aged control brain: correlation with Alzheimer pathology. Brain Research 898 (2001) 350-357
52. Toren F., and Nikki J.H. Oxidants, oxidative stress and the biology of ageing. Nature 408 (2000) 224-239
53. Townsend M., Shankar G.M., Mehta T., Walsh D.M., and Selkoe D.J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. Journal of Physiology 572 (2006) 477-492
54. Volpe B.T., Davis H.P., Towle A., and Dunlap W.P. Loss of hippocampal CA1 pyramidal neurons correlate with memory impairment in rats with ischemia or neurotoxin lesions. Behavioral Neuroscience 106 (1992) 457-464
55. Wallenstein G.V., Eichenbaum H., and Hasselmo M.E. The hippocampus as an associator of discontinuous events. Trends in Neurosciences 21 (1998) 317-323
56. Walsh D., Hartly D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A., et al. Amyloid beta-protein fibrillogenesis structure and biological activity of protofibrillar intermediates. Journal of Biological Chemistry 274 (1999) 25945-25952
57. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
58. West M.J., Coleman P.D., Flood D.G., and Troncoso J.C. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 344 (1994) 769-772
59. Wilson M.A., and McNaughton B.L. Dynamics of the hippocampal ensemble code for space. Science 261 (1993) 1055-1058
60. Wood E.R., Mumby D.G., Pinel J.P., and Philips A.G. Impaired object recognition memory in rats following ischemia-induced damage to the hippocampus. Behavioral Neuroscience 107 (1993) 51-62
61. Yan L., Yan G., Ye S., Li Z., Sumanth D., Prabhu C., et al. Cardiac functional analysis by electrocardiography, echocardiography and in situ hemodynamics in streptozotocin-induced diabetic mice. Journal of Health Science 50 (2004) 356-365
62. Zhang Y., and Herman B. Ageing and apoptosis. Mechanism of Ageing and Development 123 (2002) 245-260